InventisBio Co., Limited

益方生物科技（上海）股份有限公司

Develops small-molecule drugs for oncology, autoimmune and metabolic diseases, with a pipeline of eight candidates including TYK2 inhibitor D-2570 and SERD taragarestrant (D-0502), both in Phase III trials in China; A shares listed on the STAR Market.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Key long-term agreements
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Adverse change after the track record
• Related-party transactions and balances
• Chapter 18A biotech